[go: up one dir, main page]

WO2004008137A3 - Diagnosis and therapy of breast tumours resistant to antiestrogen treatment - Google Patents

Diagnosis and therapy of breast tumours resistant to antiestrogen treatment Download PDF

Info

Publication number
WO2004008137A3
WO2004008137A3 PCT/EP2003/007449 EP0307449W WO2004008137A3 WO 2004008137 A3 WO2004008137 A3 WO 2004008137A3 EP 0307449 W EP0307449 W EP 0307449W WO 2004008137 A3 WO2004008137 A3 WO 2004008137A3
Authority
WO
WIPO (PCT)
Prior art keywords
antiestrogen
protein
antiestrogen treatment
treatment
breast tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/007449
Other languages
French (fr)
Other versions
WO2004008137A2 (en
Inventor
Iduna Fichtner
Michael Becker
Perez Vladimir Besada
Serra Lila Castellanos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Ingenieria Genetica y Biotecnologia CIGB
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Original Assignee
Centro de Ingenieria Genetica y Biotecnologia CIGB
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10310198A external-priority patent/DE10310198A1/en
Application filed by Centro de Ingenieria Genetica y Biotecnologia CIGB, Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft filed Critical Centro de Ingenieria Genetica y Biotecnologia CIGB
Priority to AU2003253050A priority Critical patent/AU2003253050A1/en
Publication of WO2004008137A2 publication Critical patent/WO2004008137A2/en
Publication of WO2004008137A3 publication Critical patent/WO2004008137A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention is about a method to diagnose and therapy breast tumors resistant to antiestrogen treatment by using specific target proteins and the nucleic acids encoding these proteins. The method is based on the determination of the differential expression of specific target genes on the nucleic acids and protein level in antiestrogen-resistant breast tumor cells. Fields of application exist in medicine and in the pharmaceutical industry. The method is characterized by the fact, that the concentration of at least one specific target protein is determined in tumor tissue and is compared with the standard reference value of the same protein or proteins in breast tumor tissue sensitive to antiestrogen treatment, whereat a protein concentration of the sample examined lying above the standard reference value indicates tumor resistance to antiestrogen treatment, provided it is a protein which is expressed at a higher level in breast tumor cells resistant to antiestrogen treatment, as compared to breast tumor cells sensitive to antiestrogen treatment, or a protein concentration of the sample examined lying below the standard reference value indicates tumor resistance to antiestrogen treatment, provided it is a protein which is expressed at a lower level in breast tumor cells resistant to antiestrogen treatment, as compared to breast tumor cells sensitive to antiestrogen treatment.
PCT/EP2003/007449 2002-07-12 2003-07-10 Diagnosis and therapy of breast tumours resistant to antiestrogen treatment Ceased WO2004008137A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003253050A AU2003253050A1 (en) 2002-07-12 2003-07-10 Diagnosis and therapy of breast tumours resistant to antiestrogen treatment

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10231873 2002-07-12
DE10231873.5 2002-07-12
DE10310198A DE10310198A1 (en) 2002-07-12 2003-03-06 Methods for the diagnosis and therapy of anti-estrogen therapy-resistant breast tumors
DE10310198.5 2003-03-06

Publications (2)

Publication Number Publication Date
WO2004008137A2 WO2004008137A2 (en) 2004-01-22
WO2004008137A3 true WO2004008137A3 (en) 2004-09-02

Family

ID=30116640

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/007449 Ceased WO2004008137A2 (en) 2002-07-12 2003-07-10 Diagnosis and therapy of breast tumours resistant to antiestrogen treatment

Country Status (2)

Country Link
AU (1) AU2003253050A1 (en)
WO (1) WO2004008137A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2567987A1 (en) * 2004-06-18 2005-12-29 Gabriele Pestlin Use of protein pdx1 as a marker for breast cancer
CN102346190A (en) * 2011-01-24 2012-02-08 中国人民解放军第三军医大学 Double-antibody sandwich ELISA reagent kit and method for detecting hyperoxide reductase IV in biological sample and application of reagent kit

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001063292A2 (en) * 2000-02-22 2001-08-30 Board Of Regents, The University Of Texas System Compositions and methods of use of het, a novel modulator of estrogen action

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001063292A2 (en) * 2000-02-22 2001-08-30 Board Of Regents, The University Of Texas System Compositions and methods of use of het, a novel modulator of estrogen action

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BERGGREN MARGARETA I ET AL: "Thioredoxin peroxidase-1 (peroxiredoxin-1) is increased in thioredoxin-1 transfected cells and results in enhanced protection against apoptosis caused by hydrogen peroxide but not by other agents including dexamethasone, etoposide, and doxorubicin", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 392, no. 1, 1 August 2001 (2001-08-01), pages 103 - 109, XP002266115, ISSN: 0003-9861 *
HILSENBECK S G ET AL: "STATISTICAL ANALYSIS OF ARRAY EXPRESSION DATA AS APPLIED TO THE PROBLEM OF TAMOXIFEN RESISTANCE", JOURNAL OF THE NATIONAL CANCER INSTITUTE, US DEPT. OF HEALTH, EDICATIONAND WELFARE, PUBLIC HEALTH, US, vol. 91, no. 5, 26 January 1999 (1999-01-26), pages 453 - 459, XP009002755, ISSN: 0027-8874 *
KARIHTALA PEETER ET AL: "Peroxiredoxins in breast carcinoma.", CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. UNITED STATES 15 AUG 2003, vol. 9, no. 9, 15 August 2003 (2003-08-15), pages 3418 - 3424, XP002266133, ISSN: 1078-0432 *
NOH DONG-YOUNG ET AL: "Overexpression of peroxiredoxin in human breast cancer", ANTICANCER RESEARCH, vol. 21, no. 3B, May 2001 (2001-05-01), pages 2085 - 2090, XP008026146, ISSN: 0250-7005 *
SEITH P ET AL: "Novel estrogen and tamoxifen induced genes identified by SAGE (Serial Analysis of Gene Expression)", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 21, 23 January 2002 (2002-01-23), pages 836 - 843, XP002965930, ISSN: 0950-9232 *
SHOU J ET AL: "Onset of endocrine resistance in breast cancer is associated with increased actibe p38 MAPK", BREAST CANCER RESEARCH AND TREATMENT, NIJHOFF, BOSTON, US, vol. 69, no. 3, October 2001 (2001-10-01), pages 254, XP002960169, ISSN: 0167-6806 *

Also Published As

Publication number Publication date
AU2003253050A1 (en) 2004-02-02
WO2004008137A2 (en) 2004-01-22
AU2003253050A8 (en) 2004-02-02

Similar Documents

Publication Publication Date Title
Dobashi et al. Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas
WO2001040269A3 (en) Compositions and methods for therapy and diagnosis of breast cancer
WO2001000828A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
HK1045332A1 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
WO2001096390A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2005001092A3 (en) Compositions and methods for diagnosing and treating cancers
WO2001079286A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
JP2015210268A5 (en)
WO2001073027A3 (en) Compositions and methods for therapy and diagnosis of colon cancer
WO2005098046A3 (en) Methods for the determination of cell specific biomarkers
WO2005005661A3 (en) Genes regulated in ovarian cancer as prognostic and therapeutic targets
Devaraj Salivary biomarkers-a review
KR101720050B1 (en) Lung Cancer Diagnotic kit comprising primer set and probe for mutation related to lung cancer
WO2004008137A3 (en) Diagnosis and therapy of breast tumours resistant to antiestrogen treatment
WO2006081248A3 (en) Cancer markers and detection methods
WO2004053075A3 (en) Compositions, splice variants and methods relating to breast specific genes and proteins
WO2007020522A3 (en) Protein markers for diagnosing of colorectal cancer and use of said markers as drug targets for the treatment of said cancer type
CN105087794A (en) Kit for tuberculosis detection
WO2007071829A3 (en) Methods and means related to diseases
WO2002002623A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001073031A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2001096389A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2003066877A3 (en) Compositions and methods relating to hepatic specific genes and proteins
WO2002012332A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2003020899A3 (en) Compositions and methods relating to lung specific genes and proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP